

NEUROCRINE BIOSCIENCES INC  
Form 8-K  
February 27, 2004

---

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

### FORM 8-K

---

#### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): February 26, 2004

### NEUROCRINE BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

**DELAWARE**  
(State or other jurisdiction of  
incorporation or organization)

**0-28150**  
(Commission File Number)

**33-0525145**  
(IRS Employer Identification No.)

**10555 Science Center Drive, San Diego, CA**  
(Address of principal executive offices)

**92121**  
(Zip Code)

Registrant's telephone number, including area code: **(858) 658-7600**

**N/A**

(Former name or former address, if changed since last report.)

---

This Current Report on Form 8-K is filed by Neurocrine Biosciences, Inc., a Delaware corporation (the Company), in connection with the matters described herein.

#### ITEM 5. OTHER EVENTS

On February 26, 2004, the Company announced the purchase of Wyeth's entire financial interest in *indiplon*, the Company's late stage clinical development compound for the treatment of insomnia. A press release related to this is attached to this report as Exhibit 99.1 and incorporated herein by reference.

#### ITEM 7. EXHIBITS

(c) EXHIBITS. The following exhibits are filed herewith:

Exhibit	Description of Exhibit

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 8-K

Press Release dated February 26, 2004

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: February 26, 2004

/s/ Paul W. Hawran

---

Paul W. Hawran  
Executive Vice President  
and Chief Financial Officer

2

---